NMR, HPLC 99%, LCMS, COA, Pls kindly check:
Name: Maxacalcitol
CAS NO.: 103909-75-7
Chemical Formula: C26H42O4
Exact Mass: 418.3083
Elemental Analysis: C, 74.60; H, 10.11; O, 15.29
Synonym: Maxacalcitol; Maxacalcitriol; 22-Oxacalcitriol;
IUPAC/Chemical Name: (1R,3S,Z)-5-(2-((1S,3aS,7aS,E)-1-((S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
InChi Code: InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
TECHNICAL DATA
Appearance: Solid powder
Purity:99.37%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and low temperature.
Solubility: Soluble in DMSO
Drug Formulation: This drug may be formulated in DMSO
REFERENCES
1: Karakawa M, Komine M, Kishimoto M, Maki N, Matsumoto A, Sugai J, Ohtsuki M. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. J Dermatol. 2016 Nov;43(11):1354-1357. doi: 10.1111/1346-8138.13515. Epub 2016 Jul 23.
2: Tada H, Shimizu T, Nagaoka I, Takada H. Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Biomed Res. 2016;37(3):199-205. doi: 10.2220/biomedres.37.199.
3: Nakamura K, Tohyama N, Yamasaki M, Ohta H, Morishita K, Takiguchi M. Hypercalcemia in a Dog with Chronic Ingestion of Maxacalcitol Ointment. J Am Anim Hosp Assoc. 2016 Jul-Aug;52(4):256-8. doi: 10.5326/JAAHA-MS-6286. Epub 2016 Jun 3.
4: Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016 Jul;93:224.e7-224.e15. doi: 10.1016/j.urology.2016.03.008. Epub 2016 Mar 23.
5: Fujii H, Nakai K, Yonekura Y, Kono K, Goto S, Hirata M, Shinohara M, Nishi S, Fukagawa M. The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. Cardiovasc Drugs Ther. 2015 Dec;29(6):499-507.
6: Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. J Dermatol. 2016 Mar;43(3):288-93. doi: 10.1111/1346-8138.13064. Epub 2015 Aug 18.
7: Hoshina D, Tsujiwaki M, Furuya K. Successful treatment of subcorneal pustular dermatosis with maxacalcitol. Clin Exp Dermatol. 2016 Jan;41(1):102-3. doi: 10.1111/ced.12680. Epub 2015 May 19.
8: Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2015 Jun;19(3):225-34.
CAS NO.: 103909-75-7
Chemical Formula: C26H42O4
Exact Mass: 418.3083
Elemental Analysis: C, 74.60; H, 10.11; O, 15.29
Synonym: Maxacalcitol; Maxacalcitriol; 22-Oxacalcitriol;
IUPAC/Chemical Name: (1R,3S,Z)-5-(2-((1S,3aS,7aS,E)-1-((S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
InChi Code: InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
TECHNICAL DATA
Appearance: Solid powder
Purity:99.37%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and low temperature.
Solubility: Soluble in DMSO
Drug Formulation: This drug may be formulated in DMSO
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
REFERENCES
1: Karakawa M, Komine M, Kishimoto M, Maki N, Matsumoto A, Sugai J, Ohtsuki M. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. J Dermatol. 2016 Nov;43(11):1354-1357. doi: 10.1111/1346-8138.13515. Epub 2016 Jul 23.
2: Tada H, Shimizu T, Nagaoka I, Takada H. Vitamin D3 analog maxacalcitol (OCT) induces hCAP-18/LL-37 production in human oral epithelial cells. Biomed Res. 2016;37(3):199-205. doi: 10.2220/biomedres.37.199.
3: Nakamura K, Tohyama N, Yamasaki M, Ohta H, Morishita K, Takiguchi M. Hypercalcemia in a Dog with Chronic Ingestion of Maxacalcitol Ointment. J Am Anim Hosp Assoc. 2016 Jul-Aug;52(4):256-8. doi: 10.5326/JAAHA-MS-6286. Epub 2016 Jun 3.
4: Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. Urology. 2016 Jul;93:224.e7-224.e15. doi: 10.1016/j.urology.2016.03.008. Epub 2016 Mar 23.
5: Fujii H, Nakai K, Yonekura Y, Kono K, Goto S, Hirata M, Shinohara M, Nishi S, Fukagawa M. The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus. Cardiovasc Drugs Ther. 2015 Dec;29(6):499-507.
6: Umezawa Y, Nakagawa H, Tamaki K. Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial. J Dermatol. 2016 Mar;43(3):288-93. doi: 10.1111/1346-8138.13064. Epub 2015 Aug 18.
7: Hoshina D, Tsujiwaki M, Furuya K. Successful treatment of subcorneal pustular dermatosis with maxacalcitol. Clin Exp Dermatol. 2016 Jan;41(1):102-3. doi: 10.1111/ced.12680. Epub 2015 May 19.
8: Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2015 Jun;19(3):225-34.
